Brief: Simcere And JW Pharmaceutical Announce Collaboration And License Agreement For Anti-Gout Drug Candidate URC-102 In China
27/09/2019 11:53
Sept 27 (Reuters) - JW Pharmaceutical Corp 001060.KS :
* SIMCERE AND JW PHARMACEUTICAL ANNOUNCE COLLABORATION AND
LICENSE
AGREEMENT FOR ANTI-GOUT DRUG CANDIDATE URC-102 IN CHINA
* JW PHARMACEUTICAL CORP - UNDER TERMS OF AGREEMENT, JWP
WILL
RECEIVE UPFRONT PAYMENT, MILESTONES AND SALES ROYALTIES FROM
COMMERCIALIZATION IN CHINA
Source text for Eikon: ID:nPn9lvdDda
Further company coverage: 001060.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW Pharmaceutical
See all newsBrief: Jw Pharmaceutical Q3 Operating Profit 32.6 Billion Won, Up 24% From Year Earlier
Brief: Jw Pharmaceutical Q2 Operating Profit 25.4 Billion Won, Up 103.3% From Year Earlier
Brief: Jw Pharmaceutical Q1 Operating Profit 22.6 Billion Won, Down 15.4% From Year Earlier
Brief: Jw Pharmaceutical To Acquire 5 Billion Won Worth Of Own Shares
Brief: Jw Pharmaceutical To Acquire 5 Billion Won Worth Of Own Shares